Patients’ characteristics
| Characteristics | Adverse effects | |
|---|---|---|
| Present (n = 15) | Absent (n = 48) | |
| DMARDs, disease modifying antirheumatic drugs (included ciclosporin: 9 patients, hydroxychloroquine: 7 patients, and infliximab: 14 patients). | ||
| Age (years) | ||
| Mean (SD) | 56.8 (10.8) | 52.6 (16.6) |
| Range | 33–72 | 20–81 |
| Sex (F/M) | 11/4 (2.75) | 33/15 (2.2) |
| Disease | ||
| Rheumatoid arthritis | 13 | 33 |
| Psoriatic arthritis | 2 | 10 |
| Ankylosing spondylitis | – | 3 |
| Polymyositis | – | 2 |
| Disease duration (months) | ||
| Mean (SD) | 36.6 (30.1) | 35.6 (29.6) |
| Range | 2–121 | 5–120 |
| Additional drugs (No (%) of patients) | ||
| Corticosteroids (only) | 2 (13) | 7 (15) |
| Other DMARDs (± corticosteroids) | 8 (53) | 22 (46) |
| MTHFR genotype, No (%) | ||
| CC (wild type) | 10 (67) | 13 (27) |
| CT (heterozygous) | 3 (20) | 28 (58) |
| TT (homozygous) | 2 (13) | 7 (15) |